These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1150 related articles for article (PubMed ID: 20471303)

  • 1. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer.
    Mali SB
    Oral Oncol; 2015 Jun; 51(6):565-9. PubMed ID: 25817923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
    Lee TL; Yeh J; Van Waes C; Chen Z
    Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
    Yang X; Tang Z; Zhang P; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics and non-canonical aspects of JAK/STAT signalling.
    Mohr A; Chatain N; Domoszlai T; Rinis N; Sommerauer M; Vogt M; Müller-Newen G
    Eur J Cell Biol; 2012; 91(6-7):524-32. PubMed ID: 22018664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the interleukin-6/Jak/stat pathway in human malignancies.
    Sansone P; Bromberg J
    J Clin Oncol; 2012 Mar; 30(9):1005-14. PubMed ID: 22355058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
    Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
    Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
    Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
    Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.
    Waldmann TA; Chen J
    Annu Rev Immunol; 2017 Apr; 35():533-550. PubMed ID: 28182501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
    Ferrajoli A; Faderl S; Ravandi F; Estrov Z
    Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT Signaling in Glioma Cells.
    Swiatek-Machado K; Kaminska B
    Adv Exp Med Biol; 2020; 1202():203-222. PubMed ID: 32034715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled.
    Reddy EP; Korapati A; Chaturvedi P; Rane S
    Oncogene; 2000 May; 19(21):2532-47. PubMed ID: 10851052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus.
    Heim MH
    J Recept Signal Transduct Res; 1999; 19(1-4):75-120. PubMed ID: 10071751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation.
    Chaturvedi P; Reddy MV; Reddy EP
    Oncogene; 1998 Apr; 16(13):1749-58. PubMed ID: 9582023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway.
    Himpe E; Kooijman R
    Biofactors; 2009; 35(1):76-81. PubMed ID: 19319849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Activated" STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells.
    Trilling M; Le VT; Rashidi-Alavijeh J; Katschinski B; Scheller J; Rose-John S; Androsiac GE; Jonjic S; Poli V; Pfeffer K; Hengel H
    J Immunol; 2014 Jan; 192(1):447-58. PubMed ID: 24319264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential activation of JAKs, STATs and xanthine dehydrogenase/oxidase by hypoxia in lung microvascular endothelial cells.
    Wang G; Qian P; Jackson FR; Qian G; Wu G
    Int J Biochem Cell Biol; 2008; 40(3):461-70. PubMed ID: 17920330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition.
    Groner B; von Manstein V
    Mol Cell Endocrinol; 2017 Aug; 451():1-14. PubMed ID: 28576744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
    Alunno A; Padjen I; Fanouriakis A; Boumpas DT
    Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.